Hemostasis

Tx of Thrombophilia

- Clot w/ Transient RFs: AC w/ INR 2-3 x3mo
- Clot w/ No Clear RFs: AC w/ INR 2-3 x6mo
- Clot w/ Fixed RFs, Recurrent, Life-Threatening: AC w/ INR 2-3 forever
- NB malignancy related thrombophilia is resistant to Coumadin hence use heparin products
- NB even after a pt completes recommended AC period above some continue AC but to a lower INR like 1.5-2
- NB consider IVC filter in not only those with AC contraindications but also those with recurrent DVT-PE

| | Primary Hemostasis (immediate but temporary during first 12-24hrs) | | Secondary Hemostasis (slow after 12-24hrs but durable) | | |
|----------|--|---|--|--|--|
| | Vessel | Platelet (clot) | Coagulation (thrombus) | | |
| | (vasoconstriction) | Adhesion: GP Ib-IX-V on plts bind vWF | Intrinsic Pathway (12,11,9,8) w/ 12 activated by | | |
| | | and collagen in exposed endothelium | exposed endothelium = Activated Partial | | |
| | | forming a plt plug | Thromboplastin Time (aPTT) | | |
| | | Activation: Plts release ADP (inhibited | Extrinsic Pathway (3,7) w/ 3 released from injured | | |
| | | by Plavix) and TXA2 (inhibited by | cells = Prothrombin Time (PT) & International | | |
| | | Aspirin) which activate other plts (this | Normalizing Ration (INR) | | |
| | | process is inhibited by PGI2 & NO) | Common Pathway (10/5,2,1) = Thrombin Time (TT) | | |
| | | Aggregation: GP IIb-IIIa on plts | | | |
| | | crosslink w/ other GP llb/llla on plts | 12 (Hageman Factor) | | |
| | | via fibrinogen (inhibited by Integrillin) | ↓ 11 | | |
| | | | | | |
| | | | \mathbf{v} | | |
| | | | 9 3 | | |
| | | | | | |
| | | | | | |
| | | | 10/5 | | |
| | A A | | 1 | | |
| | | | 2 (Thrombin) | | |
| | | | \downarrow | | |
| | | | 1 (Fibrin aka Thrombus) w/ 13 | | |
| | | - | \checkmark | | |
| | | | FSP/DD | | |
| | | | | | |
| | | | All factors are made by liver | | |
| | | | 13 helps fibrin cross-link | | |
| | | | Inhibitors | | |
| | | | Antithrombin III (inhibits 12/11/9/10) | | |
| | | | Protein S/C (inhibits 8/5) | | |
| | Copyri | aht 2015 - Alexander <i>N</i> | O Plasmin (breaks down 1) | | |
| Site | | Small Vessels | Large Vessels | | |
| Skin | Petechiae (<2mm) v | vs Ecchymosis (2-10mm) vs Purpura (>10mm) | Hematoma | | |
| | Entire Body | Dependent Parts of Body | (Unlike those to the left these | | |
| 0.1 | Non-Blanching Palpable | Non-Blanching Non-Palpable | change colors as neme is broken down) | | |
| Other | | Superficial Skin/Mucosa | Deep Tissue | | |
| Systems | | Epistaxis, Hemoptysis | Intracranial Bleed | | |
| | | Menometrorrhagia | Hemarthrosis esp knee resulting in Arthropathy/Contractions | | |
| | GUB | | Retroperitopeal Bleed | | |
| Bleeding | Immediate after minor cuts | | Delayed/Oozing after major cuts | | |
| Labs | None 1 st Platelet Number & Smear | | 1st- PT/aPTT | | |
| | | 2 nd Platelet Function Assay (PFA-100) | • 2 nd : Fibrinogen/D-Dimer/FSP | | |
| | | which evaluates aggregation in | • 3 rd : Mixing Studies (used to determine if prolonged | | |
| | | presence of collagen and ADP | PT/aPTT is 2/2 factor deficiency or inhibitor. pt's | | |
| | | NB Bleeding Time (BT) (can increase | plasma is mixed 1:1 w/ normal pooled plasma, if a | | |
| | | w/ Quant/Qualit Plt, vWF, Capillary | factor deficiency then the deficient factor is | | |
| | | Wall problems, rarely done anymore) | restored to 50% which is enough to near normalize | | |
| | | | PT/aPTT, if an inhibitor is present then PT/aPTT will | | |
| | | | not normalize), Specific Factor Level, Specific Factor | | |
| | | | Activity (pt's plasma is mixed 1:1 w/ plasma | | |
| | | | completely deficient in the factor of interest, the | | |
| | | | difference in PT/aPTT tells how inactive the pt's | | |
| | | | plasma is) | | |

| Meds | Mechanical (refer to | Antiplatelets | Anticoagulants | | |
|------------|-------------------------|---|--|--|--|
| | DVT-PE) | COX Inhibitors | warfarin (Coumadin) | | |
| | | Aspirin (Aspirin) prevents platelet | Mechanism: interferes w/ vitK carboxylation of | | |
| | | a segregation and activation by | alutamic acid reciduos of C S 2 7 0 10 | | |
| | | aggregation and activation by | glutallic acid residues of C, S, Z, 7, 9, 10 | | |
| | | irreversibily inhibits cyclooxygenous | NB both aPTT and PT/INR are elevated but PT is | | |
| | | (both COX-1 and 2) from converting | more sensitive | | |
| | | arachidonic acids to prostaglandins | SEs: Skin (hemorrhagic bullae on breast, thighs, | | |
| | | narticularly TXA ₂ (pro-platelet) and | huttocks leading to skin necrosis when nt has | | |
| | | unfortunatoly DGL (anti-platelet) | District C/C definitions) Ob (terretorserie) Other | | |
| | | | Protein C/S deficiency), Ob (teratogenic), Other | | |
| | | however TXA_2 inhibition > PGI ₂ | (many drug-drug interactions) | | |
| | | inhibition b/c PGI₂ is made by | | | |
| | | endothelial cells which have nuclei | Heparins (activates antithrombin III, fractionated so that only | | |
| | | and thus are able to make more COX | I MW molecules which have better anti-coordilations | | |
| | | and that are able to make more cox | | | |
| | | enzyme unike TAA ₂ which is made by | properties b/c more specific for Xa, less frequent dosing, more | | |
| | | platelets which lack nuclei and thus | predictable effect hence you do not have to follow PTT, less | | |
| | | are unable to make more COX | SEs of HIT) | | |
| | | enzyme | Unfractionated Heparin (UFH) | | |
| | | dipyridamole (Persantine) similar to | Low Molecular Weight Henarin (LMWH) | | |
| | | aspirin but decreases TXA2 by | enevenarin (Lovenev) deltenarin (Eragmin) | | |
| | | increasing cAMP not by ontyme | enovaparin (Lovenov), daiteparin (Fragrini), | | |
| | | Increasing CAMP not by enzyme | tinzaparin (innonep) | | |
| | | inhibition | Factor Xa Inhibitor: fondaparinux (Arixtra) IV, | | |
| | | NB aspirin+dipyridamole (Aggrenox) | rivaroxaban (Xarelto) PO (new agent) | | |
| | | SEs: CNS (tinnitus), renal (resp | | | |
| | C | alkalosis and metabolic acidosis). Gl | Direct Thrombin Inhibitor (DTI) | | |
| | | (ulcers) other (Reve's Syndrome) | | | |
| | | (ulcers), other (nevers Syndrome) | argatroban (Argatroban) nepatically cleared | | |
| | | NB other INSAIDS bind REVERSIBLY to | Iepirudin (Refludan) renally cleared | | |
| | | COX therefore the effect is temporary | bivalirubin (Angiomax) NB only used in PCI | | |
| | | and mild at best | dabigatran (Pradaxa) PO (new agent but increased | | |
| | | ADP Inhibitors | r/o dyspepsia b/c it is prepared using acid) | | |
| | | clopidrogrel (Plavix) prevents platelet | ·/ • • / • • • • • • • • • • • • • • • • | | |
| | | activation and aggregation by | tBA (activatos plasmin) | | |
| | | irreversibly blocking ADP from | tr A (activates plasmin) | | |
| | | hinding recentors on platelets and | | | |
| | | binding receptors on platelets and | | | |
| | | irreversibly blocking fibrinogen from | | | |
| | | joining GPIIb/Illa on different | | | |
| | | platelets | | | |
| | | SEs: inhibits cytochrome P450 | | | |
| | | interfering w/ metabolism of many | | | |
| | | drugs (only w/ clonidogrel) | | | |
| | | ND ticloniding (Ticlid) no longer used | | | |
| | | • NB ticlopidine (Ticlid) no longer used | | | |
| | | b/c of r/o neutropenia and TTP | | | |
| | Convri | GPIIb/IIIa Inhibitors | aptac MD PA | | |
| | Соруп | abciximab (Reopro), tirofiban | ianias MD FA | | |
| | | (Aggrostat), eptifibatide (Integrillin) | | | |
| | | prevents platelet aggregation by | | | |
| | | blocking fibringen from joining | | | |
| | | CDUb/IIIa on different platalats | | | |
| | | | | | |
| | | Use: anti-platelet effect in ACS during | | | |
| | | PTCA | | | |
| | | SEs: thrombocytopenia | | | |
| Нуро | Vessel Damage (refer to | Platelet Dysfunction | Hypocoagulable | | |
| Hemostatic | Rheum notes) | | Elevated PT NI aPTT: Heparin, Factor Deficiency/Inhibitors | | |
| State | - | Qualitative Problems | Elevated aPTT NI PT: Factor Deficiency/Inhibitors | | |
| | | Inherited | Elevated PT/aPTT: Coumadin | | |
| | | Non Willebrand Disease (AD/V) | Classic Hemenhilis A: V linked mutation of Factor | | |
| | | • Voli vvillebrallu Disease (AD/X) | Classic Helitophillia A. A-illiked indiation of Factor | | |
| | | Bernard-Soulier Syndrome (AR | 8, 1:5,000 male pirtns, 40% have no +FHx | | |
| | | mutation of GP Ib-IX-V resulting in | suggesting high rate of germline mutations, Severe | | |
| | | inability to bind vWF on exposed | <1% vs Mod 1-5% vs Mild 5-30% activity, Tx: if mild | | |
| | | endothelium) = Giant Platelets | bleeding/dz then SC DDAVP w/ goal Factor 8 | | |
| | | Glanzmann's Thromhasthenia (AR | activity of 40% vs if severe bleeding/dz then IV | | |
| | | | Factor 8 replacement w/ goal Eactor 9 activity of | | |
| | | mutation of GP lib-lila resulting In | 750/ ND of 50/ of the devider antihedian to the | | |
| | | inability to bind crosslink with other | 75%, INB 15% OF PTS develop antibodies to the | | |
| | | plts via fibrinogen) | factor such that it is no longer effective hence the | | |
| | | Acquired | use of recombinant factors | | |
| | | Multiple Myeloma (paraprotein coats | Christmas Hemophilia B: X-linked mutation of | | |

| Copyrig | platelets inhibiting their function) Uremia 2/2 increased nitric oxide which inhibits plts, there is evidence that DDAVP and estrogens are helpful Drugs (COX/ADP/GPIIb-IIIA Inhibitors, 4th generation penicillins aka Zosyn, etc) Herbals (omega-3-FAs, garlic, onion, ginger, gingko, ginseng, etc) Quantitative Problems General 150-100k No Risk at all 100-50k Risk w/ Major Trauma or Major Surgery S0-100k Risk w/ Major Trauma or Minor Surgery/Procedures | Factor 9, just like A except less common (1/10 as common) and DDAVP does not work von Willibrand D2 (refer) dys/hypofibrinogenemia (dys = inherited excess of carbohydrate moieties, hypo = decreased amounts 2/2 liver disease or consumption, Dx: increased TT or Reptilase Time, Tx: cryo) Acquired Inhibition (can be de novo against a specific factor aka auto-antibodies, post-partum pts, pts w/ lymphoproliferative disorders, etc most commonly Factor 8, suggested by abrupt bleeding that does not correct after mixing, Tx: immunosuppressants) DIC (refer) Primary Fibrinolysis (2/2 prostate cancer or surgery, Mech: increased release of plasmin) Other Factor Deficiency (aside from 8,9 others are very rare, 11, 10 (can be acquired w/ amyloidosis), 12, 13 (completely normal labs!!!) Vit K Deficiency (2/2 (1) poor intake of green leafy vegetables or use of TPN, (2) abx associated loss of enteric bacteria, (3) malabsorption, (4) poor storage 2/2 liver dz, (5) impaired fxn (not only coumadin but also cephalosporins), Dx: corrects after 1:1 mix w/ normal plasma, Tx: PO (best), SC (variable absorption, IV (r/o anaphylaxis) vitK) Liver Disease (11) deficiency of all coag factors, only clinical important when there is acute liver failure, Tx w/ FFP, (2) cholestasis interfering w/ vitK absorption, (3) hyperfibrinolysis, Tx w/ Cryo) NB follow PT not aPTT b/c it is more sensitive Meds (above) NB there are 3 diseases that have normal labs:: certain vWD, Factor 13 deficiency, hyperfibrinolysis |
|---------|--|---|
| | Thrombocytopenia | |
| | Thrombocytopenia with Absent | |
| | Radius Syndrome | |
| | Amegakaryocytopenia with Radial- | |
| | Ulnar Synostosis | |
| | Increased Destruction | |

| | Immune/Idiopathic | |
|--------------------------------------|--|--|
| | Thrombocytopenic Purpura (ITP) | |
| | Infections HIV HSV FBV HCV CMV | |
| | | |
| | Kneum. SLE, Antiphospholipia | |
| | Syndrome, Sarcoid | |
| | Cancer: CLL, Lymphoma | |
| | Alloimmune: posttransfusion | |
| | nurnura (1-2wks post-transfusion) | |
| | | |
| | posttranspiantation | |
| | Drugs: Quinine (first documented), | |
| | Heparin (most common), GPIIa/IIIB | |
| | Inhibitors (most prominent newer | |
| | member b/c occurs much faster and | |
| | | |
| | much more severe), suids, valic, | |
| | Zyvox, AEDs, Tylenol, HCIZ, THE LIST | |
| | IS RAPIDLY EXPANDING, Usually | |
| | ~1wk of exposure is needed to | |
| | sensitize the natient (the hig | |
| | oversition is obsident (the big | |
| | | |
| | <24nrs), No specific tx other than | |
| | discontinuing the drug but if acutely | |
| | ill then consider steroids, platelet | |
| | transfusions, IVIG, plasma exchange | |
| | Infections: Ehrlichiosis. Babesiosis. | |
| | BMSE | |
| | | |
| | Vessel: Sepsis to DIC, HUS, TIP, | |
| | vasculitis, any type of vessel damage, | |
| | cavernous hemangioma | |
| | Obstetric Complications: | |
| | gestational/isolated/incidental | |
| | (common (5 10%) mild (70 150k) | |
| | (common (3-10%), mild (70-130K), | |
| | asymptomatic to mother, neonate | |
| | unaffected, occurring at during 3 rd | |
| | trimester, resolving following | |
| | delivery, no other problems, pts | |
| | a segmight also have ITP where the | |
| | thrombocytonenia is more severe and | |
| | | |
| | occurs earlier on like 1st trimester) vs | |
| | preeclampsia, eclampsia, HELLP | |
| | Blood that passes artificial surfaces: | |
| | extracorporal cardiopulmonary | |
| | bypass, CVVHD, IABP, Mechanical | AAD DA |
| | Copyright 20 - Alexander Mantas | MUYA |
| | a Splanic Converting from | |
| | Spienic Sequestration from | |
| | Hypersplenism: splenomegaly 2/2 | |
| | portal HTN, infiltrative process, Felty's | |
| | Syndrome | |
| Hyper | Platelet Hyperfunction | Hypercoagulable aka Thrombophilia |
| Hemostatic | Primary | Hyperhomocysteinemia (2.5v) measure fasting |
| State | • Moligner et /ET) | hypernomocystemenia (2.37) medsure lasting |
| State | • iviaiignancy (ET) | level, can be acquired (folate/VItB6/VItB12 |
| S/S: arterial or | Secondary/Reactive (usually don't have the | deficiency, CRF, pernicious anemia, hypoTH) to |
| multiple / | other unusual symptoms noted in ET) | inherited, Tx: lower to <10mmol/L with |
| recurrent venous | Transient (Acute Blood Loss, Rebound | folate/VitB6/VitB12 supplements, NB studies are |
| thrombi at a | from Thrombocytopenia, Acute | inconclusive if lowering homocysteine decreases |
| young age | Infection. Acute Inflammation. Post- | thrombophilia risk |
| (<50vo) and at | On Intense Eversise etc) | APC Resistance aka Factor V Arg506Gln Mutation |
| | Custoined //DA Andania Malimona | aka Eastar V Laidan (7.20v) Eastar V is resistant to |
| (abdensing) | Sustained (IDA, Aspienia, Maignancy, | and racion v Leiven (7-20x) racion v is resistant to |
| (abdominal | Chronic Infection, Chronic | degradation by activated Protein C, 3% of the |
| vessels = | Inflammation, Drug Reaction, etc) | population!!! |
| mesentery, renal | NB one of the APRs is thrombopoeitin | Prothrombin G20210A Mutation (2.8x) increased |
| vein, etc & CNS | hence any inflammatory state | prothrombin activity |
| vessels = | | Protein C/S Deficiency (10x) measure level those |
| cavernous sinus | | w/ Protoin C/S deficiency can get warfarin induced |
| dural sinus atc) | | wy Frotein C/S denciency can get Warrarin induced |
| uurai sinus etc), | | skin necrosis therefore always give heparin |
| n/o pregnancy | | products first |

| Virc of | how's Triad | | | | | • | Antithrombin III Deficiency (High Levels of Factor 8, 9, 11 Activatable Fibrinolysis Inhib | 25x) , Thrombin- ittor, and Tissue Factor |
|---|---------------|-----------------------|---------------|------------------|---------------------|--------------|---|---|
| Stat | ercoaguiable | | | | | | test for these levels | currently no labs that |
| End | othelial | | | | | • | Antiphospholipid Syndrome | (refer) |
| Dan | nage, (2) | | | | | • | Estrogen Hormones: Obesity | , OCP, HRT, Pregnancy, |
| Cha | nge in Blood | | | | | | etc | |
| Flov | w, (3) | | | | | • | Malignancy: all cancers but e | specially |
| Thr | ombophilia / | | | | | | adenocarcinomas (lung, panc | reatic, breast, ovarian, |
| • NB (| even if a pt | | | | | | GU, lymphomas, CNS, etc) b/ | c they produce |
| has | an inherited | | | | | | in migratory venous/arterial t | thrombi aka |
| RF S | 90% of these | | | | | | Trousseau's Syndrome | |
| pts | never have | | | | | • | Nephrotic Syndrome (loss of | antithrombin III) |
| an e | event | | | | | • | PNH | |
| | | | | | | • | IBD | |
| | | | | | | • | COPD | |
| | | | | | | • | Age | |
| | | | | | | | Prior Thrombotic Event | |
| | | | | | | • | High Risk Surgeries (intracran | ial. ortho. maior |
| | | | | | | | vascular, bowel resection, gas | stric bypass, renal |
| | | | | | | | transplant, etc) | |
| | | | _ | | | | (look at BUMC notes) | |
| | von Willoh | arand Disease (WMD) | | The | | | | |
| Type | Mechanism (| | Distribution | s/s | Dx | | | Treatment |
| .,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | Weibel-Palad | e bodies in | MOST | Primary and | Increased BT and At | onormal Pl | latelet Function Tests | |
| | endothelium | while Factor 8 is 🔺 | COMMON | secondary | Increased aPTT and | Decreased | d Factor 8 | |
| | made by liver |) | INHERITED | hemostasis | Quantitative Proble | em | Qualitative Problem | |
| | • (1) |) facilitates | BLEEDING | problems but | vWF:Ag Test (measu | ures | vWF:RCoF Test (functional | |
| | ad | inerence of platelets | affecting>0.1 | degree | VWE Multimer Analy | els) Veis | assay that uses control | |
| | • (2) |) stabilizes factor 8 | % of the | ucgree | (uses electrophores | is to | vWF in the presence of the | |
| | in | plasma increasing | population!!! | | separate vWF into c | lifferent | abx ristocetin cofactor to | |
| | t1 | /2 5x | | | sizes) | | assess fxn of pt's vWF) | |
| 1 | AD | | 75% | Mild Sx | + | | | DDAVP (stimulates |
| | | | | | | | | endothelial cells |
| | | | | | | | | to make vwF, |
| | | Con | vright 20 | $015 - \Delta l$ | axander M | Agente | IS MD PA | therefore only |
| | | Cob | /iigiii z\ | 15 - Ai | skunder n | Carne | | effective for 2d) |
| П | 4 Types | | 20% | Mod Sx | - | | ++ | Cryo (contains |
| | AD (A,B) | | | | | | | both vWF and |
| | AR (M,N) | | | | | | | Factor 8) |
| | | | | | | | | contraindicated |
| | | | | | | | | (the increased |
| | | | | | | | | release of |
| | | | | | | | | abnormal vWF |
| | | | | | | | | causes increased |
| | | | | | | | | uestruction of |
| | AR | | 5% | Severe Sx | +++ | | +++ | Crvo |
| | | | | | | | | NB DDAVP is |
| | | | | | | | | contraindicated |
| | | | | | | | | (same reason) |

Antiphospholipid Syndrome

• Mech

• Term used to describe the clinical relationship b/t hypercoagulable state and presence of antiphospholipid antibodies

Etiology

o Idiopathic

• Rheumatologic Disorders (SLE, Sjogren's, etc)

- Infections (HIV, HCV, etc)
- o Medications (same ones that produce lupus like syndrome)
- Malignancy (lymphoma)
- Diagnostic Criteria
 (1) >1 Cli
 - (1) <u>></u>1 Clinical Criteria
 - Vessel Thrombosis OR
 - Any type of vessel and of any size
 - Venous: DVT/PE, retinal vein occlusion, Budd-Chiari Syndrome, CNS sinuses
 - Arterial: premature CAD, CVA, renal artery thrombosis
 - o "Catastrophic Anti Phospholipid Syndrome"
 - sudden thrombosis at multiple different sites resulting in infarction of multiple organs
 - anticoagulation is not enough in this syndrome, data suggests that steroids, cyclophosphamide, IVIG and plasmapharesis might be helpful
 - Pregnancy Morbidity
 - >3 consecutive abortions before 10wks OR
 - NB abortion is nature's way of destroying a bad fetus therefore <3 is normal but when you have >3 and consecutive something wrong is going on
 - <u>>1 fetal deaths after 10wks OR</u>
 - NB fetal death after 10wks is never normal b/c if there was something wrong with the fetus nature would have destroyed it early on
 - <u>>1 premature (<34wks) birth NOT b/c of severe eclampsia or placental insufficiency</u>
 - NB pregnancy morbidity is not just 2/2 placental vessel thrombosis, it has been found that the antibodies noted below are actually trophotoxic
 - Other clinical features that are not part of diagnostic criteria and whose etiology is unclear
 - Migraine Headaches
 - Livedo Reticularis
 - Cardiac Murmurs
 - Chorea
 - Transverse Myelitis
 - (2) ≥1 Laboratory Evidence of Antiphospholipid Antibodies on ≥2 occasions and ≥12wks apart (NB also elevated PTT and thrombocytopenia (these antibodies also bind to platelets resulting in thrombocytopenia which is more confusing b/c these pts are in a pro-coagulable state))
 - Anti-Cardiolipin
 - Mechanism: exact mechanism is unclear but it is an antibody to mitochondrial phospholipids
 - NB 40% of APS pts have false positives to the VDRL test for syphilis b/c this test employs the use of cardiolipin as its reagent and these pts had anti-cardiolipin
 - Lupus Anticoagulant via Russel Viper Venom Assay
 - Mechanism: very confusing term b/c it is not specific to lupus and even though it increases the PTT test it actually is a pro-coagulant in vitro, exact mechanism is unclear but it is an antibody to phospholipids and it prolongs phospholipid dependent coagulation reactions
 - Cop Anti-Beta2-Glycoprotein Mechanism: unclear Mechanism: unclear
 - Other
 - Hemolytic Anemia
 - Adrenal Insufficiency
- Therapy
 - Strategy is controversial in terms of when and what to treat with but there are some agreed upon recommendations:
 Prophylactic anticoagulation is only indicated if the pt has had a h/o thrombosis
 - Lifelong Coumadin (INR 2-3) in the non-pregnant pt
 - ASA in the pregnant pt
 - NB hydroxychloroquine has been found to be helpful
 - Treatment
 - Difficult to use heparin b/c hard to monitor b/c PTT is already elevated thus you must monitor with a specific heparin assay

Heparin Induced Thrombocytopenia (HIT)

| | Type I | Type II |
|-----------|---------------------|---|
| Mechanism | Heparin directly | Heparin induces release of PF4 from endothelium and platelets |
| | stimulates platelet | \rightarrow |
| | clumping | Heparin–PF4 bind forming an immunogenic Ag |
| | | \downarrow |
| | | Abs against Ag are created (variable depending on the genetics of the patient and molar ratio of Heparin- |
| | | PF4 and sulphation grade of the specific Heparin) |
| | | \downarrow |

| | | ICs form and then bind to (1) endothelium causing injury and subsequent coagulation w/ macro/microvascular arterial/venous thrombosis and (2) platelets causing platelet activation and | | |
|-----------|---------------------------------------|---|--|--|
| - 1- | | consumption w/ thrombocytopenia | | |
| S/S | Asymptomatic | Symptomatic Thrombocytopenia (bleeding) | | |
| | | Arterial and Venous Thrombosis (this is actually more important than the thrombocytopenia, usually a | | |
| | | worsening of thrombosis for which heparin was administered or may be a new site, arterial thrombosis | | |
| | | specifically of the limbs/heart/brain seem to occur more commonly in pts w/ CVD while venous | | |
| | | thrombosis specifically of the DVT/brain seem to occur more commonly in post-op pts) sometimes overt | | |
| | | DIC, adrenal hemorrhage | | |
| | | Skin Manifestations (allergic type reaction and skin necrosis) | | |
| RFs | | Older Female Pt | | |
| | | Post-Op esp from CV/Ortho Procedures | | |
| | | UFH > LMWH | | |
| | | Duration >1wk | | |
| | | Concurrent Prothrombotic states | | |
| | | Full Dose > Prophylactic Dose | | |
| Duration | Transitory resolving spontaneously | Resolves anywhere from days to months and requires cessation of heparin to do so | | |
| Incidence | 20% | 2% for UFH and much lower for LMWH | | |
| Onset | After 1-4d of | After 4-10d of heparin therapy (but can occur as early as <1d if pt has had prior exposure within the past | | |
| | heparin therapy | few months b/c of amnestic response) | | |
| Platelets | 100-150k | 50-100k (but not as severe as other drug induced thrombocytopenias and thus the more common | | |
| Nadir | | complication is thrombosis NOT bleeding unlike other drug induced thrombocytopenias) | | |
| Diagnosis | | Combination of clinical likelihood (severity, recovery from drug withdrawal, onset of complications, | | |
| | | exclusion of other causes, etc), functional tests and immunologic tests | | |
| | | | | |
| | | Typically if you suspect clinically then stop heparin and Tx as below and order Immunologic Test if + then | | |
| | | confirm with Functional Test | | |
| | | | | |
| | A A | Clinical Likelihood | | |
| | | Sheridan Score, Greinacher Score | | |
| | | Immunologic Tests (testing the presence of antibodies in pt) ~100% sensitive but ~50% specific | | |
| | | HIT Ab ELISA | | |
| | | Functional Tests (testing the ability of pt's serum to activate platelets) ~50% sensitive but ~100% specific | | |
| | | Platelet Aggregation Test (PAT), 14C-Serotonin Release Assay (SRA), Heparin Induced Platelet | | |
| | | Activation (HIPA), Flow Cytometry Assay (FCA) | | |
| Treatment | It used to be | Discontinue heparins (UFH, Heparin Flushes, LMWH, Factor Xa Inhibitors) ASAP | | |
| | heparin was | b/c these pts are still at risk for thrombosis use DTIs | | |
| | continued and pts | even if you stop heparin products the antibodies are still floating around causing problems | | |
| | were just observed | if ongoing thrombotic problems consider thrombolytics. IVC filter, thrombectomy | | |
| | but now since many | do NOT give Coumadin during the acute phase and if you did then give vitK b/c risk of | | |
| | of these pts are | hemorrhagic necrotic bullae is much higher but once no longer acute (aka normal platelets) | | |
| | actually Type II it is | then pts need to be on Coumadin for 2-3 months | | |
| | honorin is | do NOT give platelets b/c can worsen thrombotic events | | |
| | discontinued | screen for lower extremity DVT | | |
| Othor | uiscontinueu | Most common type of lawsuit in cardiotheracic surgery b/c high mortality if henarin is continued | | |

Idiopathic Thrombocytopenic Purpura (ITP)

- Mechanism: autoantibodies to platelet resulting in premature clearance by the reticuloendothelial system
- NB some of these autoantibodies can also attack megakaryocytes impairing platelet production
- essentially a DOE as the test for antiplatelet glycoprotein autoantibodies aka "Platelet Associated Surface IgG Assay" has a sensitivity
 of ~55% and a specificity of 85% nevertheless still order but remember that it is a send out lab and takes weeks to come back
- typically seen in young females (always rule out HIV and HCV) but more elderly pts (>60yo) are being diagnosed and in this case a BM Bx is indicated to rule out MDS as MDS can present with an isolated thrombocytopenia
- Some very controversial studies suggest that ITP is associated w/ Helicobacter pylori infection and that eradication can lead to remission or improvement in the course of ITP
- 10% of pts have ITP + AIHI = Evan's Syndrome
- Treatment
 - Children (50%): M=F, plt<20, also accompanying eosinophilia/lymphocytosis, usually sudden onset esp after viral illness and there is a spontaneous remission rate of 75% within a few weeks therefore most argue not treating children but some do b/c kids are so active and you don't won't them getting a life threatening bleed (esp for some reason intracranial bleed)

- Young Adults (50%): F>M, plt 30-80, autoimmune process, usually insidious onset and there is a spontaneous remission rate of 5% therefore most argue treating and even when you do relapse often occurs therefore splenectomy and many other Tx are often needed
- If life threatening bleeding then...

0

- Methylprednisolone 1g IV Qd x3d over 30min
 - IVIg 1g/kg IV Qd x3d
- Platelet Transfusion
- If no life threatening bleeding then Tx if <30k otherwise just watch
 - First (~65% response rate)
 - Prednisone 1mg/kg/d PO tapered over 4-6wks
 - Anti-Rh(D) (RhoGam) Ig 75mcg/kg IV QD if Rh+ pts (essentially it just saturates spleen w/ Ig bound RBCs thus preventing the spleen from eating up platelets, the trade off is that you will have some anemia)
 - IVIg 1g/kg IV QD x3d (effect only lasts a few weeks therefore only used as a temporizing measure or bridge to splenectomy as very expensive like \$25,000, NB the response to IVIg is highly predictive of response to splenectomy)
 - Immunosuppresants esp Cyclophosphamide, Cyclosporine, IFN
 - Anti-CD20 (Rituximab) (the idea is to kill B-cells that are making the auto-antibodies)
 - If refractory to above or recurrence (~80% response rate)
 - Splenectomy (75% effective, always wait for 4-6wks allowing for above treatments to act and making sure that spontaneous remission does not occur, give Strept/Haemophilus/Neisseria vaccinations prior to surgery)
 - Staphylococcal Protein A Immunoabsorption (essentially you run the pts blood thru a column which removes IC from blood but it is rarely used anymore)
 - Danazole (an attenuated male hormone that interferes w/ macrophages from eating platelets, 60% response in males but increasing response to about 80% in elderly females)
 - AGM-531 aka N-Plate (this is NOT thrombopoietin but similar in structure and thus stimulates
 platelet production the reason why you can't use actual CSF is b/c auto-antibodies actually form
 exogenous CSF and when you stop exogenous CSF these antibodies are still around and actually
 begin to bind endogenous platelet CSF)

Thrombotic Thrombocytopenic Purpura (TTP) & Hemolytic Uremic Syndrome (HUS)

- Mechanism: problem w/ ADAMTS-13 (a protease that cleaves vWF from multimers to unimers which have LESS of a tendency to
 adhere to platelets causing microcirculation aggregation so when there is a problem w/ ADAMTS-13 you have platelet aggregation)
 resulting in Triad: F + microangiopathic hemolytic Anemia + Thrombocytopenia ("FAT-RN")
 - TTP (addition of Neurologic problems usually fluctuating MS from nl to abnl but MRI is always abnl, most common cause of M&M)
 - Defective ADAMTS-13
 - Genetic Mutation of ADAMTS-13: essentially ADAMTS-13 is unable to cleave multimers to unimers
 Inhibition of ADAMTS-13: ADAMTS-13 is inhibited by neutralizing antibodies
 - HUS (addition of Renal problems usually AKI but just sometimes hematuria/proteinuria without azotemia)
 - Overwhelmed ADAMTS-13
 - Other (90%): postpartum, metastatic cancer, post BM transplant, drug (various chemo,
 - cyclosporine, ticlopidine)
 - Infectious Diarrhea w/ EHEC-0157:H7 (10%):
 - Epidemiology: found in uncooked beef (cow is the reservoir) and thus peak during summer season, <5yo, rural, usually outbreaks but sometimes sporadic, also unpasteurized apple juice and milk, raw alfalfa sprouts, contaminated swimming pools
 - Mechanism: Shiga-like toxin → dysentery 2/2 right sided colitis BUT also (1) stimulates production of more vWF multimers which overwhelms normal ADAMTS13 causing the triad and (2) acts on the globotriaosylceramide (Gb3) receptor on renal endothelium causing renal problems,
 - \circ S/S: 20% of pts who develop bloody diarrhea develop HUS w/in 6d of onset of diarrhea
 - Tx: supportive NOT abx b/c releases more toxin creating worse HUS

Labs

0

- Normal Coags
- ADAMTS13 activity assay (low (<5% = TTP/HUS vs 5-25% other disorders like DIC, liver dz, pregnancy, etc vs >25% nl)
- ADAMTS13 inhibitor/antibody
- Tx (even if pt just has MAHA and thrombocytopenia alone this warrants Tx below, in general HUS less responsive that TTP)
 - Plasma-exchange Qd (90% remission rate) for >5d or >2d after normalization of labs, if not available than FFP, removes inhibitor/antibody and provides normal ADAMS-T13, 85% effective, primary Tx not below
 - Steroids and other immunosuppressants (cytoxan, rituxan, azathioprine, vincristine)
 - Splenectomy
 - o RRT if renal problems
 - o transfusion prn except plt b/c of the potential r/o additional microvascular occlusion

- NB don't use abx/anti-motility agents for infectious induced HUS
- Prognosis
 - 90% mortality if unTx 90%
 - o Interestingly there is high r/o recurrence often occurring several years from first episode

Disseminated Intravascular Coagulation (DIC)

- Etiology
 - o tissue damage (trauma, surgery, burns, et al which direct release of tissue factor)
 - o overwhelming infection (sepsis (most common cause), Rickettsial infection, etc with release of endotoxin)
 - malignancy (any tumor that releases TNF)
 - liquid tumors esp APML = acute DIC
 - solid tumors esp Pancreatic Cancer (Trousseau's Syndrome w/ superficial migratory thrombophlebitis and DVT-PE) = chronic DIC
 - o obstetric complications (fetal death, amniotic fluid embolism, abruption, eclampsia, et al)
 - other (peritovenous shunt used in chronic ascites, acute hemolytic transfusion reactions, PNH, rattle snake venom, heat stroke, et al)
- Pathogenesis (widespread microthrombosis vs widespread fibrinolysis)
 - (1) release enormous amounts of tissue factor which activates the extrinsic pathway → massive widespread coagulation → coagulation induces widespread platelet aggregation and agglutination (platelets)
 - (2) release enormous amounts of plasmin leading to fibrinolysis → Fibrin Degradation Products (FDPs) interfere with
 normal fibrin polymerization and platelet aggregation → the combination of increased fibrinolysis and impaired fibrin
 polymerization and thrombocytopenia leads to bleeding
 - Acute: presents as end organ ischemic damage and microangiopathic hemolytic anemia BUT bleeding also occurs as liver/BM cannot compensate quickly enough
 - Chronic: presents as end organ ischemic damage and microangiopathic hemolytic anemia BUT liver/BM is able to compensate for consumption of factors/platelets hence bleeding does not occur in chronic cases
 - End-Organ Damage: Renal, Liver, Resp, CNS
 - Other: *purpura fulminans* (large symmetric ecchymosis of the extremities but can occur anywhere w/ hemorrhagic bullae and gangrene) esp seen in meningococcemia sepsis

| | | | Acute | Chronic |
|-----|---------------------------------|------|---------------|------------|
| | | | \uparrow | = |
| VIC | aPTT | | \uparrow | = |
| | Thrombin | | \uparrow | = |
| | Fibrinogen | | \rightarrow | |
| | Platelet | | \checkmark | = |
| | FDP aka Fibrin Degradation Prod | ucts | \uparrow | \uparrow |
| | (FSP Flocculation and D-Dimer) | | | |
| | Hemolysis | | \uparrow | \uparrow |

- Treatment
 - Treat Underlying Process
 - Hemodynamic Support
 - Most pts do not require specific coagulopathic support b/c of its short duration or b/c it is not severe enough hence give FFP/Cryo/Plt only to pts who are bleeding, at high risk of bleeding, or require invasive procedures and plt<20, fibrinogen<50, INR>?, aPTT>?
 - Low Dose Heparin (only used in select chronic DIC pts)
 - o Activate Protein C (Xigris) has both anticoagulant and anti-inflammatory effects, expensive so use in severe cases
 - Protein C Concentrate (?) in pts whose cause of DIC is due to protein C deficiency
 - 65% mortality